Evidence map›Paper›PMID 24659894›Full record

ArticleWorld journal of gastroenterology2014

Mass spectrometry-based serum peptide profiling in hepatocellular carcinoma with bone metastasis.

Jian He, Zhao-Chong Zeng, Zuo-Lin Xiang, Ping Yang

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Application Value of Mass Spectrometry in the Differentiation of Benign and Malignant Liver Tumors.Medical science monitor : international medical journal of experimental and clinical research · 2017
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jian HeJian He, Zhao-Chong Zeng, Zuo-Lin Xiang, Ping Yang, Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Zhao-Chong ZengJian He, Zhao-Chong Zeng, Zuo-Lin Xiang, Ping Yang, Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Zuo-Lin XiangJian He, Zhao-Chong Zeng, Zuo-Lin Xiang, Ping Yang, Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Ping YangJian He, Zhao-Chong Zeng, Zuo-Lin Xiang, Ping Yang, Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo investigate the potential of serum peptides as a diagnostic tool for hepatocellular carcinoma (HCC) with bone metastasis.

methodsMatrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF-MS) was used to characterize the serum peptide profile of HCC patients with bone metastasis. Serum samples from 138 HCC patients (66 cases with and 72 cases without bone metastasis) were randomly assigned into a training set (n = 76) and a test set (n = 62). Differential serum peptides were examined using ClinProt magnetic bead-based purification followed by MALDI-TOF-MS. The sequences of differentially expressed serum peptides were identified using liquid chromatography-mass spectrometry. A diagnostic model was established using a learning algorithm of radial basis function neural network verified by a single blind trial. Receiver operating characteristic (ROC) analysis was performed to evaluate the diagnostic power of the established model.

resultsTen peptide peaks were significantly different between HCC patients with or without bone metastasis (P < 0.001). Sequences of seven peptides with mass to charge ratios (m/z) of 1780.7, 1866.5, 2131.6, 2880.4, 1532.4, 2489.8, and 2234.3 were successfully identified. These seven peptides were derived from alpha-fetoprotein, prothrombin, serglycin, isoform 2 of inter-alpha-trypsin inhibitor heavy chain H4, isoform 1 of autophagy-related protein 16-2, and transthyretin and fibrinogen beta chains, respectively. The recognition rate and predictive power of a diagnostic model established on the basis of six significant peptides (m/z for these six peptides were 1535.4, 1780.7, 1866.5, 2131.6, 2880.4, and 2901.9) were 89.47% and 82.89%, respectively. The sensitivity and specificity of this model based upon a single blind trial were 85.29% and 85.71%, respectively. ROC analysis found that the AUC (area under the ROC curve) value was 0.911.

conclusionOur study suggested that serum peptides may serve as a diagnosis tool for HCC bone metastasis.

Indexed as

AdultAgedAged, 80 and overBiomarkersBone NeoplasmsCarcinoma, HepatocellularCase-Control StudiesFemaleHumansLiver NeoplasmsMaleMiddle AgedPeptidesSequence Analysis, ProteinSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationYoung AdultBiomarkersPeptidesHepatocellular carcinomaMatrix-assisted laser desorption ionization-time of flight mass spectrometryPeptidesSerumTumor biomarker

Identifiers

PMID24659894
PMCPMC3961966

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.